DGAP-News: Epigenomics AG / Key word(s): Study results 20.05.2019 / 08:41 The issuer is solely responsible for the content of this announcement. New Report Shows CRC Screening Rates Increased When a Medically Underserved Population is Offered Epi proColon(R) Blood Test Data Presented at DDW 2019 Show 93.6% Acceptance Rate Among Patients Unwilling or Unable to […]
Category: Press Releases
20. May 2019
Epigenomics AG: New Report Shows CRC Screening Rates Increased When a Medically Underserved Population is Offered Epi proColon(R) Blood Test
Read more
16. May 2019
Epigenomics (ECX-DE): Key catalysts to fuel growth throughout 2019
goetzpartners securities Limited 16-May-2019 / 14:16 GMT/BST Free to access research and investor meetings in a post-MiFID2 world. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail […]
09. May 2019
Epigenomics AG: Epi proColon(R) Receives the 2019 Excellence in Molecular Diagnostics Award
DGAP-News: Epigenomics AG / Key word(s): Miscellaneous 09.05.2019 / 11:29 The issuer is solely responsible for the content of this announcement. Epi proColon Receives the 2019 Excellence in Molecular Diagnostics Award Corporate LiveWire acknowledges the importance of a patient-accepted CRC detection method to effectively diagnose colorectal cancer. Berlin (Germany) and San Diego, CA (U.S.A.), May […]
08. May 2019
Epigenomics AG Reports 2019 First Quarter Financial Results
DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement 08.05.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports 2019 First Quarter Financial Results Berlin (Germany) und San Diego, CA (U.S.A.), May 8, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”) today announced the financial […]
03. May 2019
Epigenomics AG: CMS accepts Epigenomics’ application for NCD review
DGAP-News: Epigenomics AG / Key word(s): Regulatory Admission/Miscellaneous 03.05.2019 / 10:09 The issuer is solely responsible for the content of this announcement. CMS accepts Epigenomics’ application for NCD review Berlin (Germany) and San Diego, CA (U.S.A.), May 2, 2019 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) announces that the Centers for […]
28. March 2019
Epigenomics (ECX-DE): 2018 results highlight strong underlying growth momentum
goetzpartners securities Limited 28-March-2019 / 19:54 GMT/BST Free to access research and investor meetings in a post-MiFID2 world. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail […]